Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Biosimilars in Oncology: Update Bulletin [October 2016]

Product Code:
596200639
Publication Date:
October 2016
Format:
PDF
Price:
€1010

This edition presents key opinion leader (KOL) views on recent developments in the oncology biosimilars market. Topics covered include: Mylan and Biocon presenting data at the 2016 American Society of Clinical Oncology (ASCO) conference on the HERITAGE Phase III study demonstrating that its proposed trastuzumab biosimilar MYL-1401O met the primary endpoint of response equivalency with Herceptin in metastatic breast cancer patients; Amgen and Allergan publishing top-line results from their Phase III study evaluating their proposed biosimilar ABP 980 compared with Herceptin in early-stage breast cancer; and the CVS announcement that it will remove 35 products from its standard formulary in 2017 including Amgen’s Neupogen which will be dropped in place of Novartis’ biosimilar Zarxio.

Highlights from this event update bulletin

  • Do the data presented with Mylan/Biocon’s proposed trastuzumab biosimilar MYL-1401O reassure KOLs about biosimilars in breast cancer?
  • What is the consensus on the extrapolated use of Herceptin biosimilars in breast cancer patients?
  • Why are oncologists uncomfortable about switching certain patient subgroups to biosimilars?
  • How do the experts feel about the potential superiority of Amgen/Allergan’s ABP 980 biosimilar compared to Herceptin?
  • What impact is the recent CVS Health announcement likely to have

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.




customer.service@firstwordpharma.com

All Contents Copyright © 2018 Doctor's Guide Publishing Limited All Rights Reserved